Weldegebreal Fitsum, Mitiku Habtamu, Teklemariam Zelalem
Haramaya University, College of Health and Medical Sciences, Harar, Ethiopia.
Pan Afr Med J. 2016 Jul 20;24:255. doi: 10.11604/pamj.2016.24.255.8356. eCollection 2016.
Human immunodefiecency virus infected patients did not adhere correctly to their Antiretroviral Therapy because of the drugs adverse effects. Thus, continuous evaluation of the adverse effect of Antiretroviral Therapy will help to make more effective treatment. The aim of this study was to assess the prevalence of Adverse Drug Reaction and associated factors on Antiretroviral Therapy among Human immunodefiecency virus infected Adults at Hiwot Fana Specialized University Hospital, Eastern Ethiopia.
A Hospital based retrospective study was conducted among 358 of adult patients clinical records on antiretroviral Therapy from April1 to June30, 2014.
The overall prevalence of Adverse Drug Reaction among Human immunodefiecency virus infected patients on antiretroviral Therapy was 17.0%. Of reported Adverse Drug Reaction, 80.3%, 18% and 1.7% occurred in patients on Stavudine, Zidovudine and Tenofovir based regimens respectively. The common Adverse Drug Reaction were lipodystrophy (fat change) (49.2%), numbness/tingling (27.9%), peripheral neuropathy (18%) and (8.2%) anaemia (8.2%). Patients on Stavudine containing regimens were more likely to develop Adverse Drug Reaction compared to Zidovudine (AOR = 0.212, 95% CI 0.167, 0.914, p<0.001) and Tenofovir (AOR=0.451, 95% CI 0.532, 0.948, p<0.001).
The overall prevalence of Adverse Drug Reaction among Human immunodefiecency virus infected patients in this study was 17% and more common on those patients taking Stavudine based regimen. Lipodystrophy and peripheral neuropathy were significantly associated with stavudine-based regimens, while anaemia was significantly associated with zidovudine based regimens. Thus regular clinical and laboratory monitoring of patients on Antiretroviral Therapy should be strengthened.
由于药物不良反应,感染人类免疫缺陷病毒的患者未能正确坚持抗逆转录病毒治疗。因此,持续评估抗逆转录病毒治疗的不良反应将有助于制定更有效的治疗方案。本研究的目的是评估埃塞俄比亚东部希沃特法纳专科医院感染人类免疫缺陷病毒的成年人中抗逆转录病毒治疗的药物不良反应患病率及相关因素。
对2014年4月1日至6月30日期间358例接受抗逆转录病毒治疗的成年患者的临床记录进行了一项基于医院的回顾性研究。
接受抗逆转录病毒治疗的感染人类免疫缺陷病毒患者中药物不良反应的总体患病率为17.0%。在报告的药物不良反应中,分别有80.3%、18%和1.7%发生在接受司他夫定、齐多夫定和替诺福韦治疗方案的患者中。常见的药物不良反应有脂肪代谢障碍(脂肪变化)(49.2%)、麻木/刺痛(27.9%)、周围神经病变(18%)和贫血(8.2%)。与齐多夫定(调整后比值比[AOR]=0.212,95%置信区间[CI]0.167,0.914,p<0.001)和替诺福韦(AOR=0.451,95%CI 0.532,0.948,p<0.001)相比,接受含司他夫定治疗方案的患者更易发生药物不良反应。
本研究中感染人类免疫缺陷病毒患者的药物不良反应总体患病率为17%,在接受基于司他夫定治疗方案的患者中更为常见。脂肪代谢障碍和周围神经病变与基于司他夫定的治疗方案显著相关,而贫血与基于齐多夫定的治疗方案显著相关。因此,应加强对抗逆转录病毒治疗患者的定期临床和实验室监测。